The pivotal trials leading to FDA approval demonstrated reductions in visceral adipose tissue of approximately 15 to 20% over 26 weeks in HIV lipodystrophy patients, with continued reduction at 52 weeks
IGF-1 LR3 activates the IGF-1 receptor, triggering PI3K/Akt (cell survival, mTOR, protein synthesis) and Ras/MAPK/ERK (proliferation, differentiation) cascades
Therefore, a multidisciplinary strategy should be developed to treat this complex condition, targeting both physiological and metabolic impairments
Aug 32022API CJC1295 863288-34-0 You may like CJC-1295 Whitout DAC $20.00 2026-07-25 CAS:863288-34-0 Min
Description IGF-1 LR3 1mg Research Peptide IGF-1 LR3 is supplied as a lyophilized research peptide intended for laboratory investigation and analytical applications
After reconstitution: Store at 28 C , protect from light, use aliquots to reduce handling, and avoid repeated temperature cycling